BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27973968)

  • 1. Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis.
    Parodis I; Ding H; Zickert A; Arnaud L; Larsson A; Svenungsson E; Mohan C; Gunnarsson I
    Scand J Rheumatol; 2017 Jul; 46(4):263-272. PubMed ID: 27973968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis.
    Parodis I; Ding H; Zickert A; Cosson G; Fathima M; Grönwall C; Mohan C; Gunnarsson I
    PLoS One; 2019; 14(2):e0212068. PubMed ID: 30742665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased concentration of plasma TNFR1 and TNFR2 in paediatric lupus nephritis.
    Patel M; Oni L; Midgley A; Smith E; Tullus K; Marks SD; Jones CA; Pilkington C; Beresford MW
    Lupus; 2016 Aug; 25(9):1040-4. PubMed ID: 26854079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis.
    Parodis I; Adamichou C; Aydin S; Gomez A; Demoulin N; Weinmann-Menke J; Houssiau FA; Tamirou F
    Rheumatology (Oxford); 2020 Nov; 59(11):3424-3434. PubMed ID: 32353879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.
    Mejía-Vilet JM; Arreola-Guerra JM; Córdova-Sánchez BM; Morales-Buenrostro LE; Uribe-Uribe NO; Correa-Rotter R
    J Rheumatol; 2015 Nov; 42(11):2082-91. PubMed ID: 26373566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiphospholipid Antibodies in Lupus Nephritis.
    Parodis I; Arnaud L; Gerhardsson J; Zickert A; Sundelin B; Malmström V; Svenungsson E; Gunnarsson I
    PLoS One; 2016; 11(6):e0158076. PubMed ID: 27336701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.
    Davies RJ; Sangle SR; Jordan NP; Aslam L; Lewis MJ; Wedgwood R; D'Cruz DP
    Lupus; 2013 May; 22(6):574-82. PubMed ID: 23632989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resorption of immune deposits in membranous lupus nephritis following rituximab vs conventional immunosuppressive treatment.
    Zickert A; Lannfelt K; Schmidt Mende J; Sundelin B; Gunnarsson I
    Rheumatology (Oxford); 2021 Jul; 60(7):3443-3450. PubMed ID: 33367774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial.
    Stoenoiu MS; Aydin S; Tektonidou M; Ravelingien I; le Guern V; Fiehn C; Remy P; Delahousse M; Petera P; Quémeneur T; Vasconcelos C; D'Cruz D; Gilboe IM; Jadoul M; Karras A; Depresseux G; Guillevin L; Cervera R; Cosyns JP; Houssiau FA;
    Nephrol Dial Transplant; 2012 May; 27(5):1924-30. PubMed ID: 22110048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological and outcome analysis of adult lupus nephritis patients in China.
    Tang Y; Zhang X; Ji L; Mi X; Liu F; Yang L; Qin W
    Int Urol Nephrol; 2015 Mar; 47(3):513-20. PubMed ID: 25563231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis.
    Ding H; Kharboutli M; Saxena R; Wu T
    Clin Exp Immunol; 2016 Apr; 184(1):11-8. PubMed ID: 26616478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
    Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
    Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained remission of lupus nephritis.
    Barber CE; Geldenhuys L; Hanly JG
    Lupus; 2006; 15(2):94-101. PubMed ID: 16539280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis.
    Smith E; Al-Abadi E; Armon K; Bailey K; Ciurtin C; Davidson J; Gardner-Medwin J; Haslam K; Hawley D; Leahy A; Leone V; McErlane F; Mewar D; Modgil G; Moots R; Pilkington C; Ramanan A; Rangaraj S; Riley P; Sridhar A; Wilkinson N; Beresford MW; Hedrich CM
    Lupus; 2019 Apr; 28(5):613-620. PubMed ID: 30871425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble tumor necrosis factor receptors are associated with severity of kidney dysfunction in pediatric chronic kidney disease.
    Moreira JM; da Silva AN; Marciano Vieira ÉL; Teixeira AL; Kummer AM; Simões E Silva AC
    Pediatr Nephrol; 2019 Feb; 34(2):349-352. PubMed ID: 30374604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis.
    Pinto-Peñaranda LF; Duque-Caballero V; Márquez-Hernández JD; Muñoz-Grajales C; Velásquez-Franco CJ
    Clin Rheumatol; 2015 May; 34(5):897-903. PubMed ID: 25592376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis.
    Arends S; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M; Berden JH;
    Ann Rheum Dis; 2012 Jun; 71(6):966-73. PubMed ID: 22128082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of proliferative lupus nephritis subsets in the Louvain Lupus Nephritis inception Cohort.
    Vandepapelière J; Aydin S; Cosyns JP; Depresseux G; Jadoul M; Houssiau FA
    Lupus; 2014 Feb; 23(2):159-65. PubMed ID: 24300780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus and lupus nephritis.
    Adhya Z; El Anbari M; Anwar S; Mortimer A; Marr N; Karim MY
    Lupus; 2019 May; 28(6):713-721. PubMed ID: 31046570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronicity index, especially glomerular sclerosis, is the most powerful predictor of renal response following immunosuppressive treatment in patients with lupus nephritis.
    Park DJ; Choi SE; Xu H; Kang JH; Lee KE; Lee JS; Choi YD; Lee SS
    Int J Rheum Dis; 2018 Feb; 21(2):458-467. PubMed ID: 29314776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.